



## Immune Checkpoint Inhibitor-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance

Guest Editor:

**Dr. Paul Takam Kamga**

EA4340-BCOH, Biomarker in  
Cancerology and Onco-  
Haematology, Université de  
Versailles-Saint-Quentin-En-  
Yvelines, Université Paris Saclay,  
92100 Boulogne-Billancourt,  
France

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editor

Dear Colleagues,

The use of immune checkpoint inhibitors (ICIs) including anti-PDL-1/PD-1 (Pembroluzimab, nivolumab, atezolizumab, avelumab, durvalumab), and anti-CTL4 (Ipilimumab), has shown promising results in various types of refractory solid and hematological malignancies such as melanoma, lung cancers, leukemia, and lymphoma. To fully exploit the potential of ICIs and uncover why some patients are still refractory to these promising drugs, studies are implemented to understand the molecular and cellular mechanisms related to ICI resistance or efficacy.

This Special Issue aims to address the latest findings related to the use of ICI-based immunotherapy in cancer, including treatment schedule, mechanisms of ICIs resistance, and predictive biomarkers.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)